Nirsevimab for Prevention of RSV Hospitalizations in Infants. Reply
N Engl J Med
.
2024 Mar 21;390(12):1152-1153.
doi: 10.1056/NEJMc2400983.
Authors
Saul N Faust
1
,
Simon B Drysdale
2
,
Natalya C Vassilouthis
3
;
HARMIONE Study Group
Affiliations
1
University of Southampton, Southampton, United Kingdom s.faust@soton.ac.uk.
2
St. George's University Hospitals National Health Service Foundation Trust, London, United Kingdom.
3
Sanofi, Reading, United Kingdom.
PMID:
38507766
DOI:
10.1056/NEJMc2400983
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized* / therapeutic use
Hospitalization*
Humans
Infant
Substances
nirsevimab
Antibodies, Monoclonal, Humanized